Key result
Novavax COVID-19 vaccine linked to corticosteroid-responsive acute myopericarditis in a 30-year-old man.
Why the study?
Post-vaccination myocarditis after administration of the NVX-CoV2373 COVID-19 vaccine has been reported in a limited population.
Case Report (n=1)
This report highlights a biopsy-proven case of acute myopericarditis as a potential complication of the NVX-CoV2373 COVID-19 vaccine.
May signal rare NVX-CoV2373 myopericarditis; leaves open causality and population incidence.
Post-vaccination myocarditis after administration of the NVX-CoV2373 coronavirus disease 2019 (COVID-19) vaccine has been reported in a limited population. We report the first biopsy-proven case of myopericarditis after administration of second dose of NVX-CoV2373 COVID-19 vaccine (Novavax®) in Korea. A 30-year-old man was referred to emergency department with complaints of chest pain and mild febrile sense for two days. He received the second dose vaccine 17 days ago. Acute myopericarditis by the vaccination was diagnosed by cardiac endomyocardial biopsy. He was treated with corticosteroid 1 mg/kg/day for 5 days and tapered for one week. He successfully recovered and was discharged on the 12th day of hospitalization. The present case suggests acute myopericarditis as a vaccination complication by Novavax® in Korea.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2022) conducted a case report in Acute myopericarditis (n=1). NVX-CoV2373 (Novavax) COVID-19 vaccine was evaluated on Acute myopericarditis. A 30-year-old man developed biopsy-proven acute myopericarditis 17 days after receiving the second dose of the NVX-CoV2373 (Novavax) COVID-19 vaccine, successfully recovering with corticosteroids.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: